BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday July 8 1:51 PM EDT
The new program will study acute and early infection with HIV, looking at how the virus causes disease in the very beginning of infection, how it affects the immune system, and what treatments have an effect on the amount of virus in the body and on strengthening the immune system early in the infection cycle to assure a long-term healthy state.
The research effort will include both basic and clinical work and will be called the Acute Infection and Early Disease Research Program. The principal investigator from UCSF is Jay A. Levy, MD, professor of medicine, one of the first researchers to discover the cause of AIDS, the virus that has come to be identified as HIV.
"The primary thrust of the UCSF effort will be to study early HIV pathogenesis with a focus on the amount of virus in the blood and lymph tissues during acute infection and how the immune system responds against this virus," said Levy. "Various treatments will be offered early in the infection for those who decide to receive them. We can then determine if early therapy helps and what effect treatment has on the virus, the immune response and the clinical course."
The UCSF study will evaluate the effect of therapy on: viral load, the rate at which the virus is produced, immune activation, and CD8+ T cell function. "These studies will provide insights into the pathogenesis of HIV infection and contribute to the development of new approaches for treatment," Levy said.
The new program has already begun recruiting participants. Persons interested in participating are asked to call the Options Project at San Francisco General Hospital. The Options Project, opened in July 1996, is a treatment program for persons who have been infected with HIV for less than six months.
The early intervention program is dedicated to attacking the virus in the initial phase of infection in the hope that the new therapies that are now available will be most successful when used early. The Options Project also has several other research studies available for persons with early HIV infection. The number to call for the Acute Infection and Early Disease Research Program and for information about other studies is 415/502-8100.
"The award of this grant represents the first achievement of the newly-created AIDS Research Institute (ARI) and reflects the cooperation and collaboration of many investigators from the several UCSF campuses with different areas of expertise," said Thomas Coates, PhD, UCSF professor of medicine and epidemiology and director of the ARI. "We are hopeful that this accomplishment is the first of many future successes by the ARI for these multidisciplinary approaches to find a solution to HIV and AIDS."
Five other institutions also received funding from NIAID. They are the Fred Hutchinson Cancer Center in Seattle, the Aaron Diamond AIDS Research Center in New York, the Johns Hopkins University School of Medicine in Baltimore, the University of Colorado Health Sciences Center in Denver, and the University of Alabama in Birmingham.
Levy's basic HIV research at UCSF has been supported since 1983 in part by funding from the University of California University-wide AIDS Research Project.
Co-researchers with Levy from UCSF are Margaret Chesney, PhD, professor of medicine; Michael Busch, MD, PhD, assistant professor of laboratory medicine; John Greenspan, PhD, professor of stomatology and medicine, UCSF School of Dentistry; James Kahn, MD, associate professor of medicine/SFGH; Brian Herndier, MD, PhD, assistant professor of pathology and medicine/SFGH; Michael McGrath, MD, PhD, associate professor of laboratory medicine and pathology/SFGH; Richard Price, MD, professor of neurology/SFGH; Jorge Oksenberg, PhD, assistant professor of neurology; Paul Volberding, MD, professor of medicine/SFGH; Frederick Hecht, MD, assistant professor of medicine/SFGH; Eric Vittinghoff, PhD, MPH, instructor of obstetrics and medicine; and Bruce Walker, MD, Harvard Medical School; and Bhupat Raval, PhD, Irwin Memorial Blood Centers, San Francisco.
Contact:
UCSF: Alice Trinkl, 415/476-3804
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
970708
BW970705
Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .